Australia-based Baymatob has raised AS4.215 ($3M) to continue clinical trials for its AI-guided labor monitoring device, Oli, that can predict postpartum hemorrhage, a leading cause of maternal death. The round was led by Australian Unity’s future of Healthcare Fund and supported by other institutional and high net worth investors.
Bamyatob was founded in 2013 by Dr. Sarah McDonald after her own traumatic birth experience. She explains: “It is a sad fact that mothers today are monitored with the same measures as their grandmothers. Postpartum hemorrhage is currently diagnosed by estimating blood loss after it has occurred by which point it is an emergency with damage done. There is clear evidence that devices used in labor monitoring are not helping us to improve outcomes for mothers and babies. Further they are increasing rates of unnecessary interventions and restricting mothers’ comfort and movement during labor. Yet we continue to persist with these devices to best protect in cases of litigation should things go wrong. We need to do better for mothers, babies and clinicians.”
Baymatob’s wearable device Oli uses innovative sensor technology and AI interpretation to detect a pending PPH during labor before postpartum bleeding starts. Current clinical evidence from Baymatob’s pilot study suggests that 80 percent of mothers with PPH could have clinical attention before bleeding starts using Oli, improving health outcomes and decreasing risk.
In August 2021, Oli received Breakthrough Device designation by the US Food and Drug Administration (FDA), granting the company an expedited regulatory review path and providing timely clinical access for select medical devices with potential to transform US clinical practice.
